To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2012 News Releases

About RSS

Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas' Oral JAK Inhibitor for Immunologic Diseases

October 2, 2012

Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links